IntHyx : Intubation Strategies for Patients With Acute Hypoxemic Respiratory Failure

NCT ID: NCT07189078

Last Updated: 2025-12-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-12-13

Study Completion Date

2027-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Acute hypoxemic respiratory failure requires endotracheal intubation and invasive mechanical ventilation in approximately 30-40% of cases, due to severe hypoxemia and/or clinical signs of acute respiratory distress. The primary objectives of invasive mechanical ventilation are to reduce respiratory effort and improve oxygenation. However, this intervention is also associated with both direct and indirect adverse effects, mainly linked to the need for sedation and often neuromuscular blockade. These include hemodynamic compromise, neuromuscular weakness, ventilator-induced lung injury, and infectious complications.

An ideal intubation strategy would therefore strike a balance: avoiding the risks of delayed intubation-such as refractory hypoxemia, excessive respiratory effort, and patient self-inflicted lung injury (P-SILI)-while limiting complications associated with invasive mechanical ventilation by withholding it in patients who might otherwise recover without. To date, the optimal strategy for achieving this risk-benefit balance remains uncertain.

Clinical practice suggests a broad consensus on the necessity of intubation when so-called safety criteria are met: severe hypoxemia (SaO₂/FiO₂ ratio \< 88), marked respiratory distress (use of accessory muscles, thoracoabdominal paradox, respiratory rate \> 40/min), extra-respiratory manifestations of hypoxia (e.g., altered consciousness), and/or uncontrolled hemodynamic instability. Beyond these safety thresholds, however, debate persists. Some advocate for earlier intubation-a so-called liberal approach-triggered by predefined hypoxemia criteria (e.g., SpO₂/FiO₂ \< 110), with the aim of limiting the deleterious consequences of sustained hypoxemia.

In routine practice, the criteria guiding intubation vary widely between clinicians and cannot be attributed to strong scientific evidence. This study therefore seeks to compare, in a randomized interventional design, the two main strategies currently applied across centers:

* Liberal intubation strategy: prioritizing the prevention of organ dysfunction related to hypoxemia (notably hypoxic cardiac arrest) and the risk of P-SILI.
* Restrictive intubation strategy: prioritizing the reduction of invasive mechanical ventilation use, with the goal of minimizing ventilation-related harm and its associated therapeutic burden.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Hypoxemic Respiratory Failure

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Randomization Intubation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

"Liberal" intubation strategy

Endotracheal intubation is recommended if SpO₂/FiO₂ \< 110 for more than 5 minutes.

In addition, intubation is also recommended in the liberal strategy if any of the restrictive strategy criteria occur and persist for more than 5 minutes.

Group Type EXPERIMENTAL

Liberal intubation strategy

Intervention Type PROCEDURE

Endotracheal intubation is recommended if SpO₂/FiO₂ \< 110 for more than 5 minutes.

In addition, intubation is also recommended in the liberal strategy if any of the restrictive strategy criteria occur and persist for more than 5 minutes.

Restrictive intubation strategy

Endotracheal intubation is recommended only if at least one of the following criteria persists for more than 5 minutes:

1. Respiratory rate \> 40/min, persistent use of accessory muscles, or thoracoabdominal paradox.
2. SpO₂/FiO₂ \< 88.
3. Neurological or systemic impairment attributable to hypoxemia, defined as: altered higher brain functions without another identifiable cause, Glasgow Coma Scale ≤ 12, uncontrolled hemodynamic instability, or rising lactate levels.

Group Type EXPERIMENTAL

Restrictive intubation strategy

Intervention Type PROCEDURE

Endotracheal intubation is recommended only if at least one of the following criteria persists for more than 5 minutes:

1. Respiratory rate \> 40/min, persistent use of accessory muscles, or thoracoabdominal paradox.
2. SpO₂/FiO₂ \< 88.
3. Neurological or systemic impairment attributable to hypoxemia, defined as: altered higher brain functions without another identifiable cause, Glasgow Coma Scale ≤ 12, uncontrolled hemodynamic instability, or rising lactate levels.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Restrictive intubation strategy

Endotracheal intubation is recommended only if at least one of the following criteria persists for more than 5 minutes:

1. Respiratory rate \> 40/min, persistent use of accessory muscles, or thoracoabdominal paradox.
2. SpO₂/FiO₂ \< 88.
3. Neurological or systemic impairment attributable to hypoxemia, defined as: altered higher brain functions without another identifiable cause, Glasgow Coma Scale ≤ 12, uncontrolled hemodynamic instability, or rising lactate levels.

Intervention Type PROCEDURE

Liberal intubation strategy

Endotracheal intubation is recommended if SpO₂/FiO₂ \< 110 for more than 5 minutes.

In addition, intubation is also recommended in the liberal strategy if any of the restrictive strategy criteria occur and persist for more than 5 minutes.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patient
* Patient admitted to intensive care less than 24 hours ago
* Acute respiratory failure with hypoxemia defined by either:

* Oxygen therapy ≥ 10 L/min via high-concentration mask required for SpO2 ≥ 92%
* High-flow oxygen therapy with FiO2 ≥ 50% required for SpO2 ≥ 92%
* Informed consent of the patient or a trusted relative (when the patient is unable to give consent)

Exclusion Criteria

* Acute hypercapnic respiratory failure (defined by PaCO2 \> 45 mmHg)
* Cardiogenic pulmonary edema
* Exacerbation of chronic respiratory disease
* Respiratory failure requiring long-term oxygen therapy
* Neuromuscular disease
* Glasgow Coma Scale score ≤ 12
* Decision to intubate immediately
* Invasive mechanical ventilation within the previous 7 days
* Treatment limitation decisions for intubation
* Person deprived of liberty by judicial or administrative decision : Person undergoing compulsory psychiatric care, person subject to legal protection measures, Pregnant, breastfeeding, or parturient patient
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Angers

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mathilde TAILLANTOU-CANDAU, Doctor

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Angers

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Angers University Hospital, ICU

Angers, , France

Site Status RECRUITING

Le Mans Hospital, ICU

Le Mans, , France

Site Status NOT_YET_RECRUITING

Nantes University Hospital, ICU

Nantes, , France

Site Status NOT_YET_RECRUITING

Orléans University hospital, ICU

Orléans, , France

Site Status NOT_YET_RECRUITING

Pitié-Salpétrière Hospital, Paris University Hospital, ICU

Paris, , France

Site Status NOT_YET_RECRUITING

Guadeloupe University Hospital, ICU

Pointe à Pitre, , France

Site Status NOT_YET_RECRUITING

Rennes University Hospital, ICU

Rennes, , France

Site Status NOT_YET_RECRUITING

Tours University Hospital, ICU

Tours, , France

Site Status NOT_YET_RECRUITING

Vannes Hospital, ICU

Vannes, , France

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mathilde TAILLANTOU-CANDAU, Doctor

Role: CONTACT

Phone: +33 (0)2 41 35 58 65

Email: [email protected]

Matthieu Le Lay

Role: CONTACT

Phone: +33 (0)2 41 35 58 91

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Mathilde TAILLANTOU-CANDAU, Doctor

Role: primary

Christophe GUITTON, Professor

Role: primary

Jean REIGNIER, Professor

Role: primary

Mai-Anh NAY, Doctor

Role: primary

Martin DRES, Professor

Role: primary

Frédéric MARTINO, Doctor

Role: primary

Arnaud GACOUIN, Doctor

Role: primary

Pierre-François DEQUIN, Professor

Role: primary

Agathe DELBOVE, Doctor

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2025-A01380-49

Identifier Type: OTHER

Identifier Source: secondary_id

49RC24_0293

Identifier Type: -

Identifier Source: org_study_id